RxNews Recap for 08-25-10 Print E-mail
By BioMedReports.com Staff   
Wednesday, 25 August 2010 16:52
Below is a list of the companies that made news in the healthcare sector on Wednesday, August 25, 2010.
Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.
AdvanSource Biomaterials Corporation (NYSE Amex: ASB), a leading developer, manufacturer and seller of advanced polymer technologies and materials for a broad range of medical devices, today announced that it has received a “Notice of Allowance” from the U.S. Patent and Trademark Office in connection with its antimicrobial patent application filed in June 2007. 
Bioanalytical Systems, Inc. (NASDAQ:BASI) announces that Alberto Hidalgo has joined the Company as Vice President - Business Development and Marketing effective August 18, 2010. 
Bohai Pharmaceuticals Group, Inc. (OTCBB/OTCQB: BOPH), a China-based pharmaceutical company engaged in the production, manufacturing and distribution of Traditional Chinese Medicine (TCM) in China, today announces the launch of a new corporate website for U.S. investors. 
Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer (NYSE: PFE) report that preliminary results from the Phase 3 AVERROES clinical trial of the investigational drug apixaban compared with acetylsalicylic acid (ASA, or aspirin) in patients with atrial fibrillation expected to be or demonstrated to be unsuitable for warfarin therapy will be presented at the European Society of Cardiology Congress 2010. 
Celgene Corporation (NASDAQ: CELG) today announced that information was posted on the FDA Web site indicating that an Abbreviated New Drug Application (ANDA) has been received by the Office of Generic Drugs (OGD) containing a "Paragraph IV" patent certification, for REVLIMID (lenalidomide) 25 mg capsules. 
Emergent BioSolutions Inc. (NYSE:EBS) today hosted "Looking Beyond the Bench," a symposium organized for doctoral students enrolled in the NIH-Oxford-Cambridge Scholars Program.
HIV-VAC, Inc. (PINKSHEETS: HIVV) Kevin Murray, its President, announced today that HIV-VAC has entered into a definitive agreement to acquire 80% of the outstanding voting common stock of "Richard y Lange S.A. De C.V.," a Mexican corporation for the consideration of the issuance of 8,000,000 HIV-VAC common shares.
ImageXpres Corporation (PINKSHEETS: IMJX) today reported strong second quarter financial results and provided an optimistic forecast for the second half of 2010. 
Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today it has entered into an Amended and Restated License, Development and Marketing Agreement with Allergan, Inc., which revises terms related to the PROLACRIA™ (diquafosol tetrasodium ophthalmic solution) 2% development program and Inspire's right to receive revenues from Allergan based on net sales of RESTASIS® (cyclosporine ophthalmic emulsion) 0.05% and any other human ophthalmic formulations of cyclosporine owned or controlled by Allergan. 
Metiscan, Inc. (PINKSHEETS: MTIZ), the parent company of a portfolio of enterprises with operations in healthcare, healthcare IT, mobile technology and employment services, today announces results for its second quarter ending June 30, 2010.
mPhase Technologies, Inc. (OTCBB: XDSL), a leader in the development of Smart Surfaces and Advanced Battery Technologies announced today that it has signed a representative agreement with Tritech Ltd.of Hod HaSharon, Israel.Tritech Ltd. http://www.tritech.co.il is a leading stocking representative and distributor of major manufacturers of electronic components serving the Military, Communication, Medical, Industrial Control and Security Industries.
NeoStem, Inc. (NYSE Amex:NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with operations in the U.S. and China, commented today on the ruling this week of a U.S. District Court blocking the federal government from funding research involving human embryonic stem cells. 
Neuralstem, Inc. (NYSE Amex:CUR) announced that it has filed an Investigational New Drug (IND) application with the United States Food and Drug Administration (FDA) to begin a Phase I safety clinical trial for chronic spinal cord injury with its spinal cord stem cells. 
NexMed, Inc. (Nasdaq: NEXM), backed by a revenue generating CRO business and seeking to leverage its proprietary, multi-route NexACT® drug delivery technology and internal pipeline through out-licensing arrangements and partnerships, today announced that Dr. Bassam Damaj, President and Chief Executive Officer, will present at the Rodman & Renshaw 12th Annual Healthcare Conference at 10:25am ET on Tuesday, September 14, 2010, in the Winslow Salon on the 5th floor of the New York Palace Hotel in New York City. 
PharmingGroup NV ("Pharming"or "the Company") (NYSE: PHARM) today announced that t intends to submit the Biologic License Application (BLA) to the US Food and Drug Administration(FDA) to obtain marketing approval for Rhucin® for the treatment ofacuteangioedemaattacksinpatients withHereditary Angioedema (HAE). Followingpre-BLAdiscussionswith theFDA,Pharmingis preparing the BLA dossierfor submission towards theend of this yearbut no later than January 2011. 
PPD, Inc. (Nasdaq: PPDI) today announced it has named Neil McCullough, Ph.D., as vice president of quality management systems. In this role, Dr. McCullough will provide strategic direction for quality management across all lines of business and ensure full compliance with global regulations guiding the biopharmaceutical industry.
Prana Biotechnology (NASDAQ:PRAN) announced it has secured key PBT2 patents in Europe and the United States. 
Pro-Pointer, Inc. (OTC:PPII), through its wholly-owned subsidiary Coenzyme-A Technologies, Inc.,proudly announces the introduction of their latest Nutraceutical development, the "MODULATOR MATRIX I" formula, especially designed to help the individual user to effectively cope with today's Stress and Anxiety Syndromes.
Senomyx, Inc. (NASDAQ: SNMX), a leading company focused on using proprietary taste receptor technologies to discover and develop novel flavor ingredients for the food, beverage, and ingredient supply industries, announced today that Gwen Rosenberg, the Company's Vice President, Investor Relations & Corporate Communications, will present a corporate overview on Tuesday, August 31, 2010 at 3:20 p.m. Central Time (4:20 p.m. Eastern Time) during the Midwest IDEAS Investor Conference.
SensiVida Medical Technologies (PINKSHEETS: SVMT), a developer and provider of minimally invasive diagnostic technologies and devices, announced today that it has contracted with MDC Associates to conduct clinical studies and prepare the 510k submission for SensiVida's allergy test system.
Somaxon Pharmaceuticals, Inc. (Nasdaq:SOMX) today announced that Somaxon and Procter & Gamble (NYSE:PG) have entered into a co-promotion agreement for Silenor® (doxepin), a newly-approved treatment for insomnia characterized by difficulty with sleep maintenance. 
XTend Medical Corporation (PINKSHEETS: XMDC), a company that specializes in delivering life-changing medical technology to healthcare organizations globally, has begun lining up manufacturers and software developers to commercialize the BioHarp Medical Device.
Pharmacy and football are joining forces in New York City as Walgreens (NYSE: WAG)(NASDAQ: WAG), the nation's leading provider of pharmacy, health and wellness services, today announced a strategic alliance with the New York Giants as the team's official retail pharmacy. 
ZymoGenetics, Inc. (NASDAQ:ZGEN) today announced enrollment has been completed in the Phase 2b clinical trial with PEG-Interferon lambda and ribavirin in chronic hepatitis C virus (HCV) infection. 



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter